You are no genius. At least this we can agree upon. The only rumors are the ones you are starting. Take your worthless drivel and your newly created Yahoo ID back to the Osiris message board. Thank goodness Osiris will vanish in the next few months.
I always expected Suraj and Northland were behind the heavy short interest in this stock. Who better than Northland or Landy to get them to cover? I doubt this is the primary reason that Mark Landy was brought onboard, but it can't hurt. Mark Landy might also be influential in the sale of this company.
Don't involve me in this mess. I have no desire to speak with Ozark. He never tells the truth anyhow. As a matter of fact, I have been saying for months that I wouldn't touch this stock even if I was playing with Ozark's money. I feel even stronger about that statement today than I did 6 months ago.
HF10 therapy effectively manages chronic pain without paresthesia. Nevro has a unique and effective product growing like wildfire. The FDA just approved their stimulator in May 2015. Profitability will come in the next two years. Look how easily Nevro raised money in the past ten days. I'm still holding my NuVasive stock that I purchased a few years ago. NuVasive is one of several companies likely to make an offer for Nevro in the next 18 months. I like the company, the product and the outlook. I agree with you that $72 is rich for the stock, but will there be a material pullback? There is certainly a high short interest in the stock so somebody is betting the price will drop.
Are you familiar with Nevro or their spinal stimulator approved by the FDA 13 months ago? Sales are brisk. The company seems very well run and the stock has seen a terrific rise in the past 2 years. Their technology using higher frequency seems to set their device above the competition. I'd like to buy some of the stock but I'm leery since the stock has had such a big run already.
One billion all cash deal. LDRH closed up 68% from yesterday. 2016 expected revenue of 188 million, and 2017 revenues projected at 218 million. Annual revenue growth rate under 20% and Zimmer paid 5-6 times revenues.
The REGROW Act will certainly be a game changer. I just don't give it much chance to pass in a presidential election year. The chances are much better next winter or spring.
I'll admit somebody needs to do an investigation into the Braves, but at least the Braves aren't the subject of a federal criminal investigation. The Braves biggest crime is mediocrity.
The Braves are arguably the worst team in baseball, but OSIR currently has a larger market capitalization than BATRA. What an insult to your Braves. At least they can improve. Osiris won't.
I appreciate your posts cicero but don't get your blood pressure up. We will have to wait until after the FDA hearing in September to see the share price increase most of the long term shareholders here are expecting.
Very simple but not correct. The current MiMedx revenues are from the purchase of Surgical Biologics and not from the previous MiMedx products.
I might add that Ozark and others here continue to mention that Grafix has 63% efficacy while EpiFix has only 18% efficacy. While I don't agree with that seriously flawed study, that study only makes Osiris look worse. If Osiris really had the better product, then why after 20 years are the revenues less than half of MiMedx? You would think with the better product that your revenues would be more rather than less, unless your management is totally incompetent, or your product really isn't as good as claimed.
You make a good point about Petit and MiMedx even though you might not have intended it that way. Petit took over MiMedx when the company had no revenue and built that company in about five years into a company with well over 200 million in revenues. Osiris had at best 100 million in revenues for 2015 after almost twenty years in business. I could see why Osiris found it necessary to fudge the numbers to keep up. Petit has been embarrassing every other company in the industry and making other companies look bad. It isn't hard to see why investors in Osiris view Petit as a villain. He stole your lunch money. I expect that trend will continue as well.
Osiris still claims to be the industry leader in most of their press releases. I suppose that would be true if the measurement standards were channel stuffing and delinquent financial statements.
Osiris isn't a major player except in the minds of a few of their shareholders with vivid imaginations.
Who wants a hospital anyhow that doesn't pay for product they have used? Oh wait a minute. I just answered my own question. Osiris gives product away never expecting to get paid, and then classifies it as revenue. I'm glad to see MiMedx suing a hospital to pay their overdue account. I hope the hospital pays court costs and interest too.
The FDA becomes a lot less significant if this REGROW legislation passes, and the odds on its passage are greater than most people currently think. Although it is difficult to be patient, the FDA hearing is in September and we should here something from Congress by next spring. In my opinion, the FDA would have pulled product off the market a long time ago if they were going to do it. The stock is undervalued and time is on our side.
Preventing scar tissue from forming around the sciatic nerve is huge. I only wish the previous surgeon had used AmnioFix originally. The surgeon explained that the success rate for this trimming procedure drops each time the patient has surgery because the spine is left less stable, but the existing scar tissue from the first surgery is now a big part of her problem.
Yesterday my wife and I accompanied a good friend to see a neurosurgeon because she will need back surgery. The surgeon was explaining the details of the surgery when he mentioned that he uses an amniotic membrane to prevent scar tissue from forming post surgery. I pressed him for details and he uses AmnioFix. He seemed surprised I had heard of it. He went on to say that he had great success with the product.